Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
1
|
pubmed:dateCreated |
1990-10-18
|
pubmed:abstractText |
In the French nonHodgkin's lymphoma protocols, central nervous system prophylaxis is provided by high-dose methotrexate (HD-MTX), given as a 3-hour IV infusion of 3 g/m2 MTX along with intrathecal MTX injection. The incidence of CNS relapse is less than 3%. We designed a study to evaluate the MTX transfer across the blood brain barrier in terms of cytotoxic concentrations, during these short-term infusions. Cerebrospinal fluid and plasma MTX levels were measured during 61 courses in 29 children with nonHodgkin's lymphoma; none of them had central nervous system disease. Samples were obtained either 4, 12, 18, or 24 hours after the start of HD-MTX IV infusion. A potentially cytotoxic MTX level (10(-6)M) was reached in all courses at 4 hours (median: 2.3 X 10(-6)M) and remained available in 8/16 courses at 12 hours (median: 1.0 X 10(-6)M) and in only 2/17 courses at 18 hours (median: 0.29 X 10(-6)M). Twenty-four hours after the start of HD-MTX IV infusion, CSF MTX level was always less than 10(-6)M. The plasma MTX levels were 260, 1.3, 1.0, and 1.7 X 10(-6)M at 4, 12, 18, and 24 hours, respectively. There was no correlation between plasma and CSF MTX levels. These data show that potentially cytotoxic MTX concentrations can be reached in CSF after a 3-hour IV infusion of 3 g/m2 in every patient and remain available for at least 8 hours in half of them.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:issn |
0888-0018
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
7
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
71-7
|
pubmed:dateRevised |
2004-11-17
|
pubmed:meshHeading |
pubmed-meshheading:2397170-Adolescent,
pubmed-meshheading:2397170-Child,
pubmed-meshheading:2397170-Child, Preschool,
pubmed-meshheading:2397170-Dose-Response Relationship, Drug,
pubmed-meshheading:2397170-Humans,
pubmed-meshheading:2397170-Infusions, Intravenous,
pubmed-meshheading:2397170-Lymphoma, Non-Hodgkin,
pubmed-meshheading:2397170-Methotrexate,
pubmed-meshheading:2397170-Time Factors
|
pubmed:year |
1990
|
pubmed:articleTitle |
Cerebrospinal fluid and plasma methotrexate levels following high-dose regimen given as a 3-hour intravenous infusion in children with nonHodgkin's lymphoma.
|
pubmed:affiliation |
Pediatric Oncology Department, Institut Gustave-Roussy, Villejuif, France.
|
pubmed:publicationType |
Journal Article
|